Table 2.
Factors predicting overall survival after the chemotherapy
| Univariate analysis p‐value | Hazard ratio (95% CI) | Multivariate analysis p‐value | ||
|---|---|---|---|---|
| Use of antianaerobic drug before the chemotherapy | Used | <0.001 | 1.878 (1.123–3.142) | 0.016 |
| Age | Years old | 0.031 | 0.985 (0.961–1.010) | 0.234 |
| Sex | Male | 0.341 | ||
| ECOG PS | 0 | 0.447 | ||
| Child–Pugh class C | C | 0.011 | 0.751 (0.346–1.632) | 0.253 |
| HBsAg | Positive | 0.684 | ||
| HCV‐Ab | Positive | 0.734 | ||
| Tumor number | ≥6 | 0.616 | ||
| Tumor diameter | mm | <0.001 | 1.003 (0.996–1.009) | 0.428 |
| Vascular invasion | Present | 0.002 | 1.529 (0.892–2.618) | 0.122 |
| Extrahepatic lesion | Present | <0.001 | 1.803 (0.878–3.702) | 0.109 |
| WBC | mm3 | 0.531 | ||
| AFP | ng/ml | 0.003 | 1.000 (1.000–1.000) | 0.080 |
| History of infection | Present | 0.115 | ||
| Port trouble | Present | 0.82 | ||
| Treatment with cisplatin | Treated | 0.71 |
Abbreviations: AFP, α‐fetoprotein; Anti‐HCV, antibody to hepatitis C virus; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HBsAg, hepatitis B surface antigen; WBC, white blood cell.